drugset / Trial / NCT01477567
A First-in-Human Study of LY3009385 in Healthy Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented. This study is approximately 28 days not including screening. Screening is required within 28 days prior to the start of the study.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3009385 | Unknown | 0.3 mg | Subcutaneous |
| Subject | LY3009385 | Unknown | 1 mg | Subcutaneous |
| Subject | LY3009385 | Unknown | 3 mg | Subcutaneous |
| Subject | LY3009385 | Unknown | 9 mg | Subcutaneous |
| Subject | LY3009385 | Unknown | 22 mg | Subcutaneous |
| Subject | LY3009385 | Unknown | 54 mg | Subcutaneous |